Russell Investments Group’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Russell Investments Group’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10,692	Closed	-$1.66M	–	2982
2021 Q4	$1.66M	Buy	10,692 +5,999	+128%	+$1.16M	﹤0.01%	1900
2021 Q3	$940K	Buy	4,693 +1,039	+28%	+$247K	﹤0.01%	2219
2021 Q2	$932K	Sell	3,654 -1,463	-29%	-$365K	﹤0.01%	2346
2021 Q1	$1.36M	Buy	5,117 +2,991	+141%	+$942K	﹤0.01%	2105
2020 Q4	$783K	Sell	2,126 -123	-5%	-$35.3K	﹤0.01%	2232
2020 Q3	$548K	Buy	2,249 +1,426	+173%	+$444K	﹤0.01%	2356
2020 Q2	$237K	Buy	823 +311	+61%	+$91.7K	﹤0.01%	2670
2020 Q1	$104K	Buy	+512	New	+$163K	﹤0.01%	2722
2017 Q1	–	Sell	-183	Closed	-$60K	–	3101
2016 Q4	$60K	Buy	+183	New	+$67K	﹤0.01%	2955

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Russell Investments Group's EIGR Position: Q1 2022 in Review

Russell Investments Group sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2022, closing a stake of 10,692 shares — an estimated $1.66M sold.

Russell Investments Group first reported a position in EIGR in Q4 2016 and held it in 9 quarters. The position peaked at $1.66M in Q4 2021. 94 funds tracked by Wall St. Rank hold EIGR as of Q1 2022.

Russell Investments Group reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
Russell Investments Group sold 10,692 Eiger BioPharmaceuticals, Inc. shares in Q1 2022, an estimated $1.66M.
Russell Investments Group first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2016 and held it in 9 quarters.
Russell Investments Group's Eiger BioPharmaceuticals, Inc. position peaked at $1.66M in Q4 2021.
94 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2022.

Based on Russell Investments Group's 13F filing for Q1 2022, filed 5 May 2022.